Recommendation for Calcitonin Screening in Nodular Goiter

被引:20
作者
Frank-Raue, Karin [1 ]
Schott, Matthias [2 ]
Raue, Friedhelm [1 ]
机构
[1] Endokrinol Nukl Med Praxis, Heidelberg, Germany
[2] Univ Klinikum, Funkt Bereich Spezielle Endokrinol, Dusseldorf, Germany
关键词
MEDULLARY-THYROID CANCER; SERUM CALCITONIN; CARCINOMA; DIAGNOSIS; GUIDELINES; MANAGEMENT; CALCIUM; BASAL;
D O I
10.1055/a-0585-8097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Medullary thyroid cancer (MTC) arises from parafollicular C cells of the thyroid gland and is characterized by a calcitonin secretion. Basal calcitonin correlates with the tumor mass and is used as highly sensitive and specific tumor marker for MTC. Based on former assays, unspecific calcitonin increase has frequently been seen in Hashimoto's thyroiditis, kidney insufficiency, proton pump inhibitors etc. This phenomenon is now less often seen with modern assays. The consequent use of calcitonin measurement in nodular goiter helps to identify the rare MTC at an early stage. The best cut-off values to differentiate micro-MTC from C-cell hyperplasia and other unspecific calcitonin elevations were achieved by the use of a 30pg/ml and a 60pg/ml threshold in women and men, respectively. This approach is not less sensitive than formerly used pentagastrin stimulation. A calcitonin value >100pg/ml is nearly 100% predictive for MTC. Therefore, the Thyroid Section of the German Society of Endocrinology recommends a thyroidectomy in woman with serum calcitonin values >30pg/ml (grey zone 20-30pg/ml) and in man with serum calcitonin values >60pg/ml (grey zone 30-60pg/ml). Lower calcitonin values should be re-evaluated in intervals of 3-6 months; rising calcitonin levels may indicate an MTC. In this case, thyroid operation should be performed. The cure rate of MTC with calcitonin values <100pg/ml is nearly 100% done by high volume surgeons. © Georg Thieme Verlag KG, Stuttgart. New York.
引用
收藏
页码:1065 / 1069
页数:5
相关论文
共 16 条
  • [11] Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening
    Machens, Andreas
    Dralle, Henning
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (03) : 219 - 228
  • [12] Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer
    Machens, Andreas
    Dralle, Henning
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) : 2655 - 2663
  • [13] Refining Calcium Test for the Diagnosis of Medullary Thyroid Cancer: Cutoffs, Procedures, and Safety
    Mian, Caterina
    Perrino, Michela
    Colombo, Carla
    Cavedon, Elisabetta
    Pennelli, Gianmaria
    Ferrero, Stefano
    De Leo, Simone
    Sarais, Cristiano
    Cacciatore, Chiara
    Manfredi, Gloria Irene
    Verga, Uberta
    Iacobone, Maurizio
    De Pasquale, Loredana
    Pelizzo, Maria Rosa
    Vicentini, Leonardo
    Persani, Luca
    Fugazzola, Laura
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (05) : 1656 - 1664
  • [14] Raue F, 2015, RECENT RESULTS CANC, V204, P61, DOI 10.1007/978-3-319-22542-5_3
  • [15] Usefulness of Serum Calcitonin in Patients Without a Suspicious History of Medullary Thyroid Carcinoma and with Thyroid Nodules Without an Indication for Fine-Needle Aspiration or with Benign Cytology
    Rosario, P. W.
    Calsolari, M. R.
    [J]. HORMONE AND METABOLIC RESEARCH, 2016, 48 (06) : 372 - 376
  • [16] Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
    Wells, Samuel A., Jr.
    Asa, Sylvia L.
    Dralle, Henning
    Elisei, Rossella
    Evans, Douglas B.
    Gagel, Robert F.
    Lee, Nancy
    Machens, Andreas
    Moley, Jeffrey F.
    Pacini, Furio
    Raue, Friedhelm
    Frank-Raue, Karin
    Robinson, Bruce
    Rosenthal, M. Sara
    Santoro, Massimo
    Schlumberger, Martin
    Shah, Manisha
    Waguespack, Steven G.
    [J]. THYROID, 2015, 25 (06) : 567 - 610